Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Misinterpretation of MRI findings by clinicians focused on earlier intervention is leading to increased rates of ...

Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which ...

Denmark's Novo Nordisk faces mounting pressure — from cheap copycats to US tariff threats — putting its weight-loss empire at ...

Eli Lilly acquires SiteOne Therapeutics for up to $1 billion, signaling potential uptick in Big Pharma deals and focus on ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Big Pharma is using dark money to fund groups that sound like patient advocacy organizations but represent the industry.

Apnimed will be waiting for the readout from a second Phase III trial before it approaches the FDA with an NDA for the sleep ...

The pharmaceutical giant has been racing against rivals such as Eli Lilly to dominate the highly lucrative weight-loss space. Morgan Stanley Research is projecting that the global market for ...

Eli Lilly has unveiled plans to expand its long-standing partnership with Purdue University, with the drugmaker investing up ...